PMID- 33905866
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 602
DP  - 2021 Jun 1
TI  - Development of a high payload, cancer-targeting liposomes of methyl 
      aminolevulinate for intraoperative photodynamic diagnosis/therapy of peritoneal 
      carcinomatosis.
PG  - 120612
LID - S0378-5173(21)00417-8 [pii]
LID - 10.1016/j.ijpharm.2021.120612 [doi]
AB  - Methyl aminolevulinate (MAL) is a photosensitizer topically used for photodynamic 
      diagnosis (PDD) and photodynamic therapy (PDT) of skin pre-cancers and cancers. 
      In this study, our goal is to expand the application of MAL to dual 
      intraoperative PDD and PDT of peritoneal carcinomatosis. A new liposomal MAL 
      formulation (lipMAL) designed for systemic or intraperitoneal administration was 
      developed. LipMALs prepared by ammonium sulfate gradient technique achieved MAL 
      payload up to 18% (w/w) with drug encapsulation efficiency in the range of 
      15.1-31.5%. All lipMALs demonstrated controlled MAL release behavior, and 
      achieved strong fluorescence in cancer cells (SKOV3) but minimal fluorescence in 
      non-cancer peritoneal cells (B14FAF28-G3). LipMALs led to significantly higher 
      fluorescence levels than free MAL groups (P < 0.05), up to 6.8-fold of the free 
      MAL fluorescence levels in SKOV3 cells. The PDD performance of lipMALs was also 
      compared with free MAL in SKOV3/ B14FAF28-G3 co-cultures simulating ovarian 
      cancer micrometastases on peritoneal surface. The lipMAL-treated cancer colonies 
      glew more brightly than the free MAL treated colonies and were clearly 
      distinguishable from the dim peritoneum background with unaided eyes. LipMAL also 
      achieved significantly stronger anticancer PDT effects than free MAL both in 
      terms of cell viability and colony-formation (P < 0.05) while demonstrating 
      minimal dark toxicity. To conclude, a new promising aid for the surgeons to 
      achieve more complete resection of tumors and PC micrometastases and clean up any 
      residual cancer cells undetected was developed.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Luan, Shijie
AU  - Luan S
AD  - Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 
      North Broad Street, Philadelphia, PA 19140, USA.
FAU - Tran, Ngoc T
AU  - Tran NT
AD  - Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 
      North Broad Street, Philadelphia, PA 19140, USA.
FAU - Xue, Hui-Yi
AU  - Xue HY
AD  - Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 
      North Broad Street, Philadelphia, PA 19140, USA. Electronic address: 
      joannex@temple.edu.
FAU - Wong, Ho-Lun
AU  - Wong HL
AD  - Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 
      North Broad Street, Philadelphia, PA 19140, USA. Electronic address: 
      ho-lun.wong@temple.edu.
LA  - eng
PT  - Journal Article
DEP - 20210424
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Liposomes)
RN  - 0 (Photosensitizing Agents)
RN  - 88755TAZ87 (Aminolevulinic Acid)
SB  - IM
MH  - Aminolevulinic Acid
MH  - Humans
MH  - Liposomes
MH  - *Peritoneal Neoplasms/drug therapy
MH  - *Photochemotherapy
MH  - Photosensitizing Agents/therapeutic use
MH  - *Skin Neoplasms/drug therapy
OTO - NOTNLM
OT  - Liposomes
OT  - Methyl aminolevulinate
OT  - Peritonealcarcinomatosis
OT  - Photodynamic diagnosis
OT  - Photodynamic therapy
EDAT- 2021/04/28 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/04/27 20:12
PHST- 2020/11/30 00:00 [received]
PHST- 2021/03/26 00:00 [revised]
PHST- 2021/04/11 00:00 [accepted]
PHST- 2021/04/28 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2021/04/27 20:12 [entrez]
AID - S0378-5173(21)00417-8 [pii]
AID - 10.1016/j.ijpharm.2021.120612 [doi]
PST - ppublish
SO  - Int J Pharm. 2021 Jun 1;602:120612. doi: 10.1016/j.ijpharm.2021.120612. Epub 2021 
      Apr 24.